Oruka Therapeutics COO Sandler sells $167,821 in shares
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices climb amid boost to safe haven demand after U.S.-Iran escalation Stocks end mixed in a solid rebound from initial slide on U.S.-Iran conflict Dollar surges to over five-week high on U.S.-Iran escalation; euro, sterling slip Gold price surge after Iran attack could fade, Pepperstone says FLASH SALE (South Africa Philippines Nigeria) FLASH SALE Oruka Therapeutics COO Sandler sells $167,821 in shares By Investing.com Insider Trading Published 03/02/2026, 06:55 PM Oruka Therapeutics COO Sandler sells $167,821 in shares 0 ORKA -2.09% Oruka Therapeutics NASDAQ:ORKA Chief Operating Officer Laura Lee Sandler sold 5,000 shares of common stock on March 2, 2026, for a total value of $167,821. The shares were sold in two transactions, with prices ranging from $32.66 to $34.33. The first sale involved 2,325 shares sold at a weighted average price of $33.2843, with prices ranging from $32.66 to $33.64. The second sale consisted of 2,675 shares at a weighted average price of $33.8077, with prices ranging from $33.66 to $34.33. On the same day, Sandler also exercised warrants to acquire 5,000 shares of Oruka Therapeutics stock at a price of $7.80 per share, for a total of $39,000. These warrants are part of an employee warrant plan and will expire on July 14, 2034. The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. The insider sale comes as Oruka shares trade at $33.69, up 232% over the past year and 117% in the last six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, placing it among the most overvalued stocks tracked by the platform. The company reports earnings in four days.Following these transactions, Sandler directly owns 237,584 shares of Oruka Therapeutics. The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on Septembe...
Read full article at source